Neuropeptide proenkephalin A is associated with in-hospital mortality in patients with acute intracerebral hemorrhage

Yang, Xin-Gang; An, Hailong; Zhang, Jianmin

doi:10.1016/j.peptides.2014.06.005

Cited by 5 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 In addition, there is evidence from studies in patients with other cerebrovascular diseases such as spontaneous intra-cerebral hemorrhage or SAH, which showed that high PENK-A plasma levels were independently associated with unfavorable outcome. [10][11][12] In contrast, in the unadjusted analyses, we only found an association of PENK-A levels with an unfavorable outcome (mRS > 2), suggesting that the association was confounded by demographic and other vascular risk factors. Compared to the above-mentioned smaller study (n ¼ 124), 13 the current study analyzed almost 2.5 times as many patients (n ¼ 320).…”

Section: Discussionmentioning

confidence: 89%

“…9 A product of the precursor peptide PENK-A is elevated in patients with acute stroke and was associated with poor outcome in intracranial hemorrhage (n ¼ 202) or subarachnoid hemorrhage (SAH; n ¼ 360). [10][11][12] Another study (n ¼ 189) suggested that PENK-A plasma levels might serve as a good prognostic marker in patients with acute stroke for unfavorable outcome. 13 Thus, a higher PENK-A plasma level might be associated with poor clinical outcome in patients with acute stroke.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Proenkephalin A Adds No Incremental Prognostic Value After Acute Ischemic Stroke

Gruber

Schweizer

Luft

et al. 2020

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Objective: The aim of this study was to confirm previous observations that proenkephalin A (PENK-A) may serve as prognostic marker in the setting of acute ischemic stroke in a large stroke cohort. Methods: The plasma concentration of PENK-A was measured within 72 hours of symptom onset in 320 consecutively enrolled patients with stroke. The primary outcome measures were unfavorable functional outcome (modified Rankin Scale score 0-2 vs 3-6) and mortality within 90 days. Logistic and cox proportional regression analyses were fitted to estimate odds ratios (ORs), hazard ratios (HRs) and 95% confidence intervals (CIs), respectively, for the association between PENK-A and the primary outcome measures. Results: After adjusting for demographic and vascular risk factors, PENK-A was neither independently associated with functional outcome (OR: 1.29, 95% CI: 0.16-10.35) nor mortality (HR: 1.02, 95% CI: 0.14-7.33). Conclusion: Among patients with acute stroke, PENK-A does not serve as an independent prognostic marker in this external validation cohort.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Proenkephalin A Adds No Incremental Prognostic Value After Acute Ischemic Stroke

Gruber

Schweizer

Luft

et al. 2020

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Yalcin et al have shown that serum proenkephalin may be used as a predictor of mortality in patients with traumatic brain injury [12]. Associations between elevated penKid levels and functional outcome as well as mortality in patients with traumatic brain injury, ischaemic-and hemorrhagic stroke have also been found [13][14][15][16]. A combination of renal dysfunction and brain injury that might explain penKid elevation in critically ill patients has not been explored.…”

mentioning

confidence: 99%

Plasma proenkephalin A 119–159 on intensive care unit admission is a predictor of organ failure and 30-day mortality

Frigyesi

Lengquist

et al. 2021

ICMx

View full text Add to dashboard Cite

Background Proenkephalin A 119-159 (penKid) has been suggested as a marker of renal failure and poor outcome. We aimed to investigate the association of penKid on ICU admission with organ dysfunction and mortality in a mixed ICU population. In this retrospective, observational study, admission penKid levels from prospectively collected blood samples of consecutive patients admitted to four Swedish ICUs were analysed. The association of penKid with day-two sequential organ failure assessment (SOFA) scores and 30-day mortality was investigated using (ordinal) logistic regression. The predictive power of penKid for 30-day mortality and dialysis was assessed using the area under the receiver operating characteristic curve (AUC). Results Of 1978 included patients, 632 fulfilled the sepsis 3-criteria, 190 had a cardiac arrest, and 157 had experienced trauma. Admission penKid was positively associated with 30-day mortality with an odds ratio of 1.95 (95% confidence interval 1.75–2.18, p < 0.001), and predicted 30-day mortality in the entire ICU population with an AUC of 0.71 (95% confidence interval 0.68–0.73) as well as in the sepsis, cardiac arrest and trauma subgroups (AUCs of 0.61–0.84). Correction for admission plasma creatinine revealed that penKid correlated with neurological dysfunction. Conclusion Plasma penKid on ICU admission is associated with day-two organ dysfunction and predictive of 30-day mortality in a mixed ICU-population, as well as in sepsis, cardiac arrest and trauma subgroups. In addition to being a marker of renal dysfunction, plasma penKid is associated with neurologic dysfunction in the entire ICU population, and cardiovascular dysfunction in sepsis.

show abstract

Endogenous opiates and behavior: 2014

Bodnar

2016

Peptides

View full text Add to dashboard Cite

Neuropeptide proenkephalin A is associated with in-hospital mortality in patients with acute intracerebral hemorrhage

Cited by 5 publications

References 22 publications

Proenkephalin A Adds No Incremental Prognostic Value After Acute Ischemic Stroke

Proenkephalin A Adds No Incremental Prognostic Value After Acute Ischemic Stroke

Plasma proenkephalin A 119–159 on intensive care unit admission is a predictor of organ failure and 30-day mortality

Endogenous opiates and behavior: 2014

Contact Info

Product

Resources

About